RIBA在慢性丙型病毒性肝炎中的应用价值

THE APPLIED SIGNIFICANCE OF RECOMBINANT IMMUNOBLOT ASSAY IN CHRONIC HEPATITIS C

采用含ＨＣＶ三种抗原（Ｃ_（２２），Ｃ_（３３），Ｃ_（１００））的重组免疫印迹试验（ＲＩＢＡ）检测了７１例抗－ＨＣＶ阳性（ＲＩＡ－２法）的慢性非甲非乙型肝炎患者血清并与ＨＣＶＲＮＡ结果进行了比较。ＲＩＢＡ阳性５６例，可疑８例，对应ＨＣＶＲＮＡ检出率分别为９４．６４％（５３／５６）和３７．５％（３／８），ＲＩＢＡ阴性的７例均未检出ＨＣＶ ＲＮＡ。ＨＣＶＲＮＡ阳性病例中ＲＩＢＡ多为阳性，可疑仅占５．３６％（３／５６），无１例阴性。可见，ＲＩＢＡ阳性即表示ＨＣＶ感染且存在病毒血症，ＲＩＢＡ可作为第二代ＲＩＡ或ＥＬＩＳＡ查抗－ＨＣＶ的确证实验。

Seventy one chronic non-A non-B hepatitis patients with anti-HCV positive(RIA-2) were tested for antibodies against individual HCV recombinant antigens(C_22 ,C_33c, C_100)with recom binant immunoblot assay (RIBA) and analysed as compared with the results of serum HCV RNA.Fifty six patients were RIBA positive, 8 were indeterminate, The positive rate of HCV RNA was 94.64% (53/56) in patients with RIBA positive,and 37.5%(3/8) in patients with indeterminate RIBA result.None of the patients with RIBA negative was positive for HCV RNA. Most of the patients with HCV RNA positive were positive for RIBA,only 3 cases were indeterminate, no one was negative for RIBA.These results indicate that RIBA may be used as a confirmative test for the second generation test of anti-HCV, and positive result of RIBA means HCV viremia.